Summary Among women with node-negative breast cancer and small tumours, it is important to identify those with tumours that will recur, so that they may receive adjuvant therapy, while 
The need to identify breast cancer patients who will benefit from adjuvant therapy, and to spare others the side-effects, is spurring the evaluation of new prognostic indicators. Adjuvant therapy prolongs the lives of many women with breast cancer. But because it is difficult to determine which patients' tumours will recur, many patients who do not need treatment receive it nevertheless (Reynolds, 1994) .
Thanks in part to earlier detection, nearly two-thirds of newly diagnosed breast cancer cases have no lymph node involvement. Of the 120 000 women every year in this situation, 70-80% can be cured without adjuvant therapy. How to locate the remaining 20-30% of node-negative patients who should be given adjuvant therapy remains a dilemma (Reynolds, 1994) .
Tumour size, histological grading, node involvement, lymphatic invasion (Leitner et al., 1995) and oestrogen receptor (ER) status of the tumour are the most widely accepted and widely used indicators employed to assess the probability of tumour recurrence and the need for adjuvant therapy. Other markers, such as tumour epidermal growth factor receptor, tumour c-erbB-2 level, and tumour angiogenesis, are also used (Reynolds, 1994) . However, many of these markers are highly intercorrelated, so the information they provide can be redundant (Reynolds, 1994) .
A need exists to identify and develop independent predictors of tumour recurrence. This task is impeded by the complex biological interactions involved in breast cancer, and the concomitant difficulty in predicting which potential markers will provide the best prognostic information.
In (Katz et al., 1994 (Katz et al., , 1995 .
Approximately 30% of breast cancer cells produce PSA (Monne et al., 1994; Yu et al., 1994 Yu et al., , 1995 Diamandis et al., 1994 ). Therefore, we tested the PSA RT-PCR assay on blood specimens from women with breast cancer.
Patients and methods
We evaluated 78 women at Mount Sinai Medical Center with histologically confirmed breast cancer. Patients were selected if the extent of the disease was known and a peripheral blood specimen was available. The mean age of the patients was 59+ 15 years (mean + s.d.). The youngest woman was 31 and the oldest was 94.
RNA preparation Venous blood (5 cm3) from the women was collected in ethylene diaminetetraacetic acid (EDTA)-treated collection tubes. The whole blood was subjected to a gradiant isolation of nucleated cells using Ficoll (Accurate Chemical and Scientific Corp, Westbury, NY, USA) (Moreno et al., 1992) . The mononuclear cell layer was aspirated, rediluted in phosphate-buffered saline, and then centrifuged as previously described (Moreno et al., 1992) . After the supernatant was discarded, the pellet was stored at -700C or used directly for RNA extraction. After adding 2 ml of RNAzol B (Biotecx Laboratories, Houston, TX, USA) and 0.2 ml of chloroform to the pellet, the preparation was mixed vigorously and put on ice for 5 min. The suspension was then centrifuged at 12 000 g (4°C) for 15 min. by tumour cells in tissue and blood samples (Ghossein et al., 1995) . RT-PCR of keratin 19 (K19) transcripts has been used to detect occult breast cancer in peripheral blood and bone marrow (Datta et al., 1994) . RT-PCR of MUCI mRNA, which encodes a core protein of polymorphic epithelial mucin, has been employed for the detection of micrometastases in axillary lymph nodes of breast cancer patients (Noguchi et al., 1994) . In this study, we used RT-PCR amplification of PSA mRNA in peripheral blood of women with different stages of breast cancer. PSA is a kallikrein-like protease that is produced in prostatic epithelial cells and breast tumour cells, as well as some ovarian, liver, kidney, adrenal, colon, parotid and lung tumours . Furthermore, recent evidence indicates that PSA is a molecule produced by cells bearing steroid hormone receptors under conditions of steroid hormone stimulation .
The presence of a PSA fragment that can be amplified was an early event in many of our breast cancer cases (Figure 1 ). Twenty-two per cent of cases that had been diagnosed less than 12 months before were PSA positive. This finding provides support for the theory that breast cancer is a systemic disease from its inception (Fisher, 1980) . The proportion of cases in which a PSA fragment could be amplified (18 of 78) seems relatively high, given that Yu et al. (1994) detected PSA in 30% of female and male breast tumours. However, Yu et al. used immunoassay, which is consistently less sensitive than the RT-PCR we employed.
As noted above, we could amplify the PSA fragment from 7 of 29 node-negative localised cases with small tumours, both ER positive and ER negative. We conclude that PSA RT-PCR may be a useful method for determining the presence of circulating metastatic cells in some women with node-negative breast cancer, and the potential for these women to develop recurrent disease and thus benefit from adjuvant therapy. Indeed, Katz et al. (1995) have shown that circulating metastatic prostate cancer cells, detected by PSA RT-PCR, are a risk factor for recurrent disease in men with prostate cancer. We recommend that the role of the PSA RT-PCR assay in breast cancer, as described in this article, be investigated further.
